Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.48 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.48 |
| ▸ | DPAGT1 | Q9H3H5 | 2/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30256182 | 1.00 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3DPAGT1 | |
| SCHEMBL19401548 | 1.00 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3DPAGT1 | |
| SCHEMBL19401549 | 1.00 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3DPAGT1 | |
| SCHEMBL30256620 | 1.00 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3DPAGT1 | |
| SCHEMBL25752513 | 0.93 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3DPAGT1 | |
| SCHEMBL31278694 | 0.89 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3DPAGT1 | |
| SCHEMBL19397204 | 0.89 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3DPAGT1 | |
| SCHEMBL19397206 | 0.89 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3DPAGT1 | |
| SCHEMBL25739842 | 0.89 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3DPAGT1 | |
| SCHEMBL25739843 | 0.89 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3DPAGT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780874-B2 | Nucleoside derivative and use thereof | YAMASA CORPORATION (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20200385419-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | YAMASA CORPORATION (JP) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385419-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | NSUN2, NSUN3, ADAR | SLC28A1 20/4885SLC28A2 33/4885SLC29A1 22/4885 |
| US-11780874-B2 | Nucleoside derivative and use thereof | NSUN2, NSUN3, ADAR | SLC28A1 20/4885SLC28A2 33/4885SLC29A1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.